Retatrutide 30mg
Currently in Phase III clinical trials — the most advanced metabolic research compound of its kind. Retatrutide targets three receptor systems simultaneously, a first-of-its-kind approach that produced significant results in published Phase II data.
How It Works
The Target
Three metabolic receptors simultaneously: GLP-1, GIP, and Glucagon. This triple-agonist approach is unique — most compounds target only one or two.
The Mechanism
GLP-1 activation enhances insulin release when blood sugar is elevated. GIP amplifies this effect and influences fat storage signaling. Glucagon receptor activation increases energy expenditure and fat oxidation in the liver. Together, they create a coordinated metabolic response across multiple organ systems.
Why It Matters
Phase II trials showed the triple mechanism produced significantly greater effects than single or dual agonists alone, suggesting the three pathways work synergistically rather than just additively.
Specifications
| Purity | >=98% (HPLC) |
| MW | ~4.8 kDa |
| Form | Lyophilized white powder |
| Storage | -20 degrees C, protect from light |
| Reconstitution | Bacteriostatic water |
| Shelf Life | 24 months lyophilized |
Published References
Read the full Retatrutide research article →